Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of rare disease patents

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11642468 Medicament injection device with rotary encoder	Patent 11642468 was granted and assigned to Sanofi on May, 2023 by the United States Patent and Trademark Office.	Sanofi	Sanofi	United States Patent and Trademark Office	11642468	May 9, 2023
‌ US Patent 11248056 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11248056 was granted and assigned to Dyne Therapeutics on February, 2022 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11248056	February 15, 2022
‌ US Patent 11497815 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11497815 was granted and assigned to Dyne Therapeutics on November, 2022 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11497815	November 15, 2022
‌ US Patent 11771776 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11771776 was granted and assigned to Dyne Therapeutics on October, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11771776	October 3, 2023
‌ US Patent 11833217 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11833217 was granted and assigned to Dyne Therapeutics on December, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11833217	December 5, 2023
‌ US Patent 10155027 Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease	Patent 10155027 was granted and assigned to Amicus Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10155027	December 18, 2018
‌ US Patent 11369689 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11369689 was granted and assigned to Dyne Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11369689	June 28, 2022
‌ US Patent 10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene	Patent 10076514 was granted and assigned to Amicus Therapeutics on September, 2018 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10076514	September 18, 2018
‌ US Patent 12119091 Utilizing masked autoencoder generative models to extract microscopy representation autoencoder embeddings	Patent 12119091 was granted and assigned to Recursion Pharmaceuticals on October, 2024 by the United States Patent and Trademark Office.	Recursion Pharmaceuticals	Recursion Pharmaceuticals	United States Patent and Trademark Office	12119091	October 15, 2024
‌ US Patent 11679161 Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy	Patent 11679161 was granted and assigned to Dyne Therapeutics on June, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11679161	June 20, 2023
‌ US Patent 11787869 Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness	Patent 11787869 was granted and assigned to Dyne Therapeutics on October, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11787869	October 17, 2023
‌ US Patent 11633496 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11633496 was granted and assigned to Dyne Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11633496	April 25, 2023
‌ US Patent 11986537 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 11986537 was granted and assigned to Dyne Therapeutics on May, 2024 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11986537	May 21, 2024
‌ US Patent 11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene	Patent 11833164 was granted and assigned to Amicus Therapeutics on December, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11833164	December 5, 2023
‌ US Patent 11911484 Muscle targeting complexes and uses thereof for treating myotonic dystrophy	Patent 11911484 was granted and assigned to Dyne Therapeutics on February, 2024 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11911484	February 27, 2024
‌ US Patent 12005124 Muscle targeting complexes and uses thereof for treating dystrophinopathies	Patent 12005124 was granted and assigned to Dyne Therapeutics on June, 2024 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	12005124	June 11, 2024
‌ US Patent 11623916 Highly purified batches of pharmaceutical grade migalastat and methods of producing the same	Patent 11623916 was granted and assigned to Amicus Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11623916	April 11, 2023
‌ US Patent 10251873 Methods of treating fabry patients having renal impairment	Patent 10251873 was granted and assigned to Amicus Therapeutics on April, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10251873	April 9, 2019
‌ US Patent 10537564 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene	Patent 10537564 was granted and assigned to Amicus Therapeutics on January, 2020 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10537564	January 21, 2020
‌ US Patent 11406761 Injector device	Patent 11406761 was granted and assigned to Sanofi on August, 2022 by the United States Patent and Trademark Office.	Sanofi	Sanofi	United States Patent and Trademark Office	11406761	August 9, 2022
‌ US Patent 11286305 Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA	Patent 11286305 was granted and assigned to Dyne Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11286305	March 29, 2022
‌ US Patent 11369732 Packaging assembly	Patent 11369732 was granted and assigned to Sanofi on June, 2022 by the United States Patent and Trademark Office.	Sanofi	Sanofi	United States Patent and Trademark Office	11369732	June 28, 2022
‌ US Patent 11969475 Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy	Patent 11969475 was granted and assigned to Dyne Therapeutics on April, 2024 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11969475	April 30, 2024
‌ US Patent 11759525 Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy	Patent 11759525 was granted and assigned to Dyne Therapeutics on September, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11759525	September 19, 2023
‌ US Patent 11629197 Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness	Patent 11629197 was granted and assigned to Dyne Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Dyne Therapeutics	Dyne Therapeutics	United States Patent and Trademark Office	11629197	April 18, 2023

...

Results per page:

1,647 results

0 selected

1,647 results

0 selected